Literature DB >> 7994605

Differential expression of HLA-DRB genes according to the polymorphism of their regulatory region.

P Louis1, V Pinet, P Cavadore, S Kerlan-Candon, J Clot, J F Eliaou.   

Abstract

The polymorphism of the HLA-class II molecules is directly involved in the specificity of the antigen presentation. We have previously described an allelic polymorphism in the proximal promoter region of the HLA-DRB genes. In this study, we demonstrate that this polymorphism has functional consequences on the transcriptional activity of the promoter of the different DRB genes. Indeed, transiently transfected DRB gene promoters into human B cell lines showed a marked difference in their ability to induce transcription of the chloramphenicol acetyl transferase (CAT) reporter gene. These findings suggest the presence of two interdependent effects of the HLA-class II molecules on the specificity of the immune response: one corresponding to the allelic polymorphism of the peptide-binding site and the second resulting from the polymorphism of the promoter regions inducing a variable expression of the DRB genes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7994605

Source DB:  PubMed          Journal:  C R Acad Sci III        ISSN: 0764-4469


  3 in total

1.  Reassessing the role of HLA-DRB3 T-cell responses: evidence for significant expression and complementary antigen presentation.

Authors:  Rosa Faner; Eddie James; Laurie Huston; Ricardo Pujol-Borrel; William W Kwok; Manel Juan
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

Review 2.  Regulation of major histocompatibility complex class II gene expression, genetic variation and disease.

Authors:  L Handunnetthi; S V Ramagopalan; G C Ebers; J C Knight
Journal:  Genes Immun       Date:  2009-11-05       Impact factor: 2.676

3.  HLA-DRB1 may be antagonistically regulated by the coordinately evolved promoter and 3'-UTR under stabilizing selection.

Authors:  Benrong Liu; Yonggui Fu; Zhifen Wang; Sisi Zhou; Yu Sun; Yuping Wu; Anlong Xu
Journal:  PLoS One       Date:  2011-10-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.